公開日期 | 標題 | 作者 | 來源出版物 | scopus | WOS | 全文 |
2010 | Early alpha-fetoprotein response predicts treatment efficacy of antiangiogenic systemic therapy in patients with advanced hepatocellular carcinoma | YU-YUN SHAO ; ZHONG-ZHE LIN ; CHIUN HSU ; Ying-Chun Shen ; CHIH-HUNG HSU ; ANN-LII CHENG | Cancer | 141 | 148 | |
2019 | Early alpha‐foetoprotein response associated with treatment efficacy of immune checkpoint inhibitors for advanced hepatocellular carcinoma | YU-YUN SHAO ; TSUNG-HAO LIU ; CHIUN HSU ; LI-CHUN LU ; YING-CHUN SHEN ; ZHONG-ZHE LIN ; ANN-LII CHENG ; CHIH-HUNG HSU | Liver International | 56 | 58 | |
2021 | Early Changes in DCE-MRI Biomarkers May Predict Survival Outcomes in Patients with Advanced Hepatocellular Carcinoma after Sorafenib Failure: Two Prospective Phase II Trials | BANG-BIN CHEN ; ZHONG-ZHE LIN ; YU-YUN SHAO ; CHIUN HSU ; CHIH-HUNG HSU ; ANN-LII CHENG ; PO-CHIN LIANG ; TIFFANY TING-FANG SHIH | Cancers | 4 | 3 | |
2017 | Early perfusion changes within 1 week of systemic treatment measured by dynamic contrast-enhanced MRI may predict survival in patients with advanced hepatocellular carcinoma | BANG-BIN CHEN ; CHAO-YU HSU ; CHIH-WEI YU ; PO-CHIN LIANG ; CHIUN HSU ; CHIH-HUNG HSU ; ANN-LII CHENG ; TIFFANY TING-FANG SHIH | European Radiology | 15 | 17 | |
2020 | Efficacy and Safety of Ramucirumab in Asian and Non-Asian Patients with Advanced Hepatocellular Carcinoma and Elevated Alpha-Fetoprotein: Pooled Individual Data Analysis of Two Randomized Studies | Yen C.-J.; Kudo M.; Lim H.-Y.; CHIH-HUNG HSU ; Vogel A.; Brandi G.; Cheng R.; Nitu I.S.; Abada P.; Hsu Y.; Zhu A.X.; Kang Y.-K. | Liver Cancer | 12 | 10 | |
2010 | Efficacy and tolerability of bevacizumab plus capecitabine as first-line therapy in patients with advanced hepatocellular carcinoma | CHIH-HUNG HSU ; Yang T.-S.; CHIUN HSU ; Toh H.C.; Epstein R.J.; Hsiao L.-T.; PEI-JER CHEN ; ZHONG-ZHE LIN ; Chao T.-Y.; ANN-LII CHENG | British Journal of Cancer | 114 | 112 | |
2012 | Efficacy, safety, and potential biomarkers of thalidomide plus metronomic chemotherapy for advanced hepatocellular carcinoma | YU-YUN SHAO ; ZHONG-ZHE LIN ; CHIUN HSU ; Lee, Kuan-Der; Hsiao, Chi-Huang; YEN-SHEN LU ; Huang, Chien-Chung; YING-CHUN SHEN ; CHIH-HUNG HSU ; ANN-LII CHENG | Oncology | 26 | 25 | |
2021 | Eg5 as a Prognostic Biomarker and Potential Therapeutic Target for Hepatocellular Carcinoma | YU-YUN SHAO ; Sun, Nai-Yun; YUNG-MING JENG ; YAO-MING WU ; CHIUN HSU ; CHIH-HUNG HSU ; Hsu, Hey-Chi; ANN-LII CHENG ; ZHONG-ZHE LIN | Cells | 3 | 2 | |
2023 | Embracing anti-PD-1 immunotherapy in the treatment of esophageal cancer: Implications of positive phase III trials in advanced and resected esophageal cancer | HUNG-YANG KUO ; JHE-CYUAN GUO ; CHIH-HUNG HSU | Journal of the Formosan Medical Association = Taiwan yi zhi | 2 | 2 | |
2023 | Erdafitinib in patients with advanced solid tumours with FGFR alterations (RAGNAR): an international, single-arm, phase 2 study | Pant, Shubham; Schuler, Martin; Iyer, Gopa; Witt, Olaf; Doi, Toshihiko; Qin, Shukui; Tabernero, Josep; Reardon, David A; Massard, Christophe; Minchom, Anna; Lugowska, Iwona; Carranza, Omar; Arnold, Dirk; Gutierrez, Martin; Winter, Helen; Stuyckens, Kim; Crow, Lauren; Najmi, Saltanat; Hammond, Constance; Thomas, Shibu; Santiago-Walker, Ademi; Triantos, Spyros; Sweiti, Hussein; Loriot, Yohann; CHIH-HUNG HSU | The Lancet. Oncology | 18 | | |
2007 | Esophageal adenocarcinoma arising from Barrett's epithelium in Taiwan | CHIA-HUNG TU ; Lee C.-T.; Perng D.-S.; Chang C.-C.; CHIH-HUNG HSU ; YI-CHIA LEE | Journal of the Formosan Medical Association | 7 | 5 | |
2022 | Expanding Sorafenib Treatment for Hepatocellular Carcinoma Beyond Barcelona Clinic Liver Cancer Stage C Patients: A National Study | Chen, Ching-Tso; CHIH-HUNG HSU ; ANN-LII CHENG ; YU-YUN SHAO | Anticancer research | 0 | 0 | |
2012 | Factors impacting prognosis prediction in BCLC stage C and Child-Pugh Class A hepatocellular carcinoma patients in prospective clinical trials of systemic therapy | ZHONG-ZHE LIN ; CHIUN HSU ; Hu F.-C.; YU-YUN SHAO ; DWANG-YING CHANG ; CHIH-HSIN YANG ; RUEY-LONG HONG ; CHIH-HUNG HSU ; ANN-LII CHENG | Oncologist | 8 | 10 | |
2007 | Gemcitabine and ifosfamide as a second-line treatment for cisplatin-refractory metastatic urothelial carcinoma: A phase II study | CHIA-CHI LIN ; CHIH-HUNG HSU ; CHAO-YUAN HUANG ; Keng H.-Y.; YU-CHIEH TSAI ; KUO-HOW HUANG ; ANN-LII CHENG ; YEONG-SHIAU PU | Anti-Cancer Drugs | 32 | 29 | |
2013 | The germline BIM deletion polymorphism is not associated with the treatment efficacy of sorafenib in patients with advanced hepatocellular carcinoma | YU-YUN SHAO ; Chang Y.-L.; Huang C.-Y.; CHIH-HUNG HSU ; ANN-LII CHENG | Oncology (Switzerland) | 5 | 5 | |
2017 | Hepatitis C virus core protein potentiates proangiogenic activity of hepatocellular carcinoma cells | YU-YUN SHAO ; MIN-SHU HSIEH ; Wang, Han Yu; Li, Yong Shi; Lin, Hang; Hsu, Hung Wei; Huang, Chung Yi; CHIH-HUNG HSU ; ANN-LII CHENG | Oncotarget | 12 | 9 | |
2011 | High circulating endothelial progenitor levels associated with poor survival of advanced hepatocellular carcinoma patients receiving sorafenib combined with metronomic chemotherapy | YU-YUN SHAO ; ZHONG-ZHE LIN ; Chen T.-J.; CHIUN HSU ; Ying-Chun Shen ; CHIH-HUNG HSU ; ANN-LII CHENG | Oncology | 17 | 17 | |
2017 | High plasma interleukin-6 levels associated with poor prognosis of patients with advanced hepatocellular carcinoma | YU-YUN SHAO ; Lin H.; Li Y.-S.; Lee Y.-H.; Chen H.-M.; ANN-LII CHENG ; CHIH-HUNG HSU | Japanese Journal of Clinical Oncology | 34 | 31 | |
2015 | High serum transforming growth factor-β1 levels predict outcome in hepatocellular carcinoma patients treated with sorafenib | Lin T.-H.; YU-YUN SHAO ; Chan S.-Y.; Huang C.-Y.; CHIH-HUNG HSU ; ANN-LII CHENG | Clinical Cancer Research | 78 | 78 | |
2002 | High-frequency microsatellite instability predicts better chemosensitivity to high-dose 5-fluorouracil plus leucovorin chemotherapy for stage IV sporadic colorectal cancer after palliative bowel resection | JIN-TUNG LIANG ; KUO-CHIN HUANG ; HONG-SHIEE LAI ; PO-HUANG LEE ; Cheng Y.-M.; Hsu H.-C.; ANN-LII CHENG ; CHIH-HUNG HSU ; KUN-HUEI YEH ; Wang S.-M.; Tang C.; KING-JEN CHANG | International Journal of Cancer | 109 | 98 | |